Sontra and EpiVax collaborate to develop topical vaccines

By Angela McDaniels

Seattle, Oct. 20 - Sontra Medical Corp. and EpiVax, Inc. said they have formed a research collaboration to investigate the topical delivery of EpiVax's therapeutic HIV vaccine and other DNA vaccines using Sontra's SonoPrep skin permeation device.

EpiVax has developed tools that combine bioinformatics with immunology to sequence proteins and identify the specific protein components that are responsible for creating a protective immune response

Sontra said its SonoPrep ultrasonic skin permeation device employs low-frequency ultrasound to penetrate the skin's outermost layer and allow molecules to pass through with 100 times greater efficiency than intact skin.

Sontra is a biotechnology company based in Franklin, Mass., that develops skin permeation technology for use in transdermal drug delivery and diagnosis.

EpiVax is a biopharmaceutical company based in Providence, R.I., that creates vaccines and therapeutic proteins for use in treating infectious diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.